118 related articles for article (PubMed ID: 26267949)
1. [Immunotherapy and cancers: last news from the front (Asco 2015)].
Nau JY
Rev Med Suisse; 2015 Jun; 11(480):1410-1. PubMed ID: 26267949
[No Abstract] [Full Text] [Related]
2. [Not Available].
Ostendorf GM
Versicherungsmedizin; 2016 Mar; 68(1):31-3. PubMed ID: 27111958
[No Abstract] [Full Text] [Related]
3. Advances and outlooks for immunotherapy of cancer.
Steplewski Z
Hybridoma; 1993 Oct; 12(5):493-500. PubMed ID: 8300120
[No Abstract] [Full Text] [Related]
4. Therapeutic use of monoclonal antibodies: a new era?
Zucca E
Ann Oncol; 1998 Jul; 9(7):683-5. PubMed ID: 9739430
[No Abstract] [Full Text] [Related]
5. First conference on cancer immunotherapy gets "explosion of interest".
Hawkes N
BMJ; 2015 Sep; 351():h4876. PubMed ID: 26362316
[No Abstract] [Full Text] [Related]
6. [Immunology: new approaches to immuno-modulation and immunotherapy].
Kabelitz D
Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1471-3. PubMed ID: 16794979
[No Abstract] [Full Text] [Related]
7. Immunotherapy: the last 25 years.
Plunkett TA; Miles DW
Cancer Treat Rev; 1999 Dec; 25(6):355-63. PubMed ID: 10644501
[No Abstract] [Full Text] [Related]
8. Immunotherapy in cancer care: understanding the impact of shifting treatment paradigms in the managed care setting.
Weber J; Kolodziej MA; George DJ; Salgo P
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E4. PubMed ID: 25618618
[No Abstract] [Full Text] [Related]
9. Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley JL; Dahut WL
Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
[No Abstract] [Full Text] [Related]
10. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
11. International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.
Berraondo P; Aznar MA; Perez-Ruiz E; Rodriguez-Ruiz ME; Castañon E; Perez-Gracia JL; Melero I
Cancer Immunol Immunother; 2018 Nov; 67(11):1809-1813. PubMed ID: 30182281
[No Abstract] [Full Text] [Related]
12. Immunotherapy: Immune-modified response criteria - an iterative learning process?
Ott PA
Nat Rev Clin Oncol; 2018 May; 15(5):267-268. PubMed ID: 29532797
[No Abstract] [Full Text] [Related]
13. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
14. [Cancer immunotherapy].
Vakkila J; Pihkala U
Duodecim; 1999; 115(7):785-94. PubMed ID: 11859512
[No Abstract] [Full Text] [Related]
15. Immunotherapy's cancer remit widens.
Ledford H
Nature; 2013 May; 497(7451):544. PubMed ID: 23719439
[No Abstract] [Full Text] [Related]
16. Immunotherapy: hype and hope.
The Lancet Oncology
Lancet Oncol; 2018 Jul; 19(7):845. PubMed ID: 30084367
[No Abstract] [Full Text] [Related]
17. [Regulatory T cells in cancer immunotherapy].
Nishikawa H
Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785
[No Abstract] [Full Text] [Related]
18. Next steps for cancer immune therapy.
Cancer Discov; 2015 Mar; 5(3):221-2. PubMed ID: 25710919
[No Abstract] [Full Text] [Related]
19. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
20. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
